Hosting an SNF Starting Grant applicant
The Department of oncology UNIL CHUV (DO) and the Lausanne branch of the Ludwig Institute for Cancer Research (LICR) will support the application of a candidate for a Starting Grant from the Swiss National Science Foundation (SNSF).
The SNSF deadline for submission is 1st February 2023. Interested applicants should therefore send their CV with a five-page summary of their research proposal, prepared according to SNSF guidelines, by 27th November to firstname.lastname@example.org.
Preselected candidates will be informed by 4th December and invited to give a presentation, followed by discussions with individual members of the department.
The successful applicant will complement and fit into the existing fundamental experimental research landscape at the department. The areas of particular interest include tumor immunology and the tumor microenvironment, cell engineering, translational oncology, synthetic biology and immunotherapy, and systems immune biology
The DO comprises twenty-two research groups leading cutting edge basic and translational research in the field of tumor immunology and the tumor microenvironment as well as six affiliated research groups specialized in protein and cell engineering, translational oncology, and radiopharmaceutical sciences. The clinical services of the department include medical oncology, radiation oncology, haematology, immuno-oncology as well as centers of experimental therapeutics and precision oncology. The department is home to one of four world branches of the Ludwig Institute for Cancer Research, a renowned international non-profit organization dedicated to the prevention and control of cancer through basic and translational research. The DO is a founding member of the Swiss Cancer Centre Léman, which brings together the University of Lausanne, the University of Geneva, the EPFL (Ecole Polytechnique Fédérale de Lausanne) and clinical institutions of the Lake Geneva region in a scientific and clinical alliance dedicated to the fight against cancer.
The key strengths of the department include outstanding expertise in cancer immune biology and immunotherapy, full integration into the scientific community of bioengineers, computational scientists and cancer biologists at UNIL and EPFL and a vibrant clinical community dedicated to the development of innovative cancer immunotherapies. This singular integrated and highly collaborative environment creates unparalleled opportunities for leading a world-class cancer research program.
The successful applicant will be hosted in a new LICR building at the Epalinges site and will benefit from an outstanding research infrastructure, exceptional scientific environment and financial support during the 6th year of the position